Sun Pharma unveils acne drug Absorica LD in US

"The launch of Absorica LD - which offers the proven efficacy and safety of Absorica at a lower dose - underscores our commitment to making a difference in the lives of people with severe recalcitrant nodular acne," Sun Pharma North America CEO Abhay Gandhi said.

New Delhi: Pharma major Sun Pharmaceutical Industries said it has launched Absorica LD capsules used for management of severe nodular acne in the US market.

The product launched by company's wholly-owned subsidiaries for the management of severe recalcitrant nodular acne in patients of 12 years of age and older, it can be taken with or without food, Sun Pharma said in a filing to BSE.

Also Read: Sun Pharma, Rockwell Medical Ink Licensing Pact For Triferic In India

"The launch of Absorica LD - which offers the proven efficacy and safety of Absorica at a lower dose - underscores our commitment to making a difference in the lives of people with severe recalcitrant nodular acne," Sun Pharma North America CEO Abhay Gandhi said.

Absorica LD is the only isotretinoin formulation to feature company's micronisation technology, which utilises micronised particles to optimise absorption at a 20 per cent lower dose, Sun Pharma said.

Also Read: Sun Pharma Plea To Refix Price Of Ciprofloxacin Hydrochloride Injection Rejected